Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04939935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2026 to Dec 2030
    • Study sites: 40 to 49
    • Study completion date: May 2027 to Dec 2030
    v16
  2. Site details revised at 16 of 40 sitesv15
  3. Study sites: 16 to 40v14
  4. Site contacts updated at 1 of 16 sitesv13
  5. Study sites: 13 to 16v12
Show 10 earlier versionsHide 10 earlier versions
  1. Site details revised at 1 of 13 sitesv11
  2. Study sites: 12 to 13
    • Eligibility criteria revised
    v10
  3. Site details revised at 4 of 12 sitesv9
  4. Site details revised at 1 of 12 sites
    • Eligibility criteria expanded, about 2 words
    v8
  5. Site details revised at 5 of 12 sitesv7
  6. Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Enrollment target: 1164 to 1174
    • Study sites: 4 to 12
    • Start date changed from estimate of Nov 2022 to Nov 29, 2022
    • Study description revised
  7. Primary completion date: Dec 2025 to Dec 2026
    • Start date: Jul 2022 to Nov 2022
    • Study completion date: Dec 2026 to May 2027
    v5
  8. Start date: Apr 2022 to Jul 2022v4
  9. Start date: Aug 2021 to Apr 2022
    • Eligibility criteria expanded, about 6 words
    • Site contacts updated at 3 of 4 sites
    v3
  10. Study title expanded, about 11 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function decline, reducing morbidity and mortality and improving the quality of life for ADPKD patients.
Trial Details
NCT Number NCT04939935
Lead Sponsor The University of Queensland
Conditions
(from sponsor)		 Autosomal Dominant Polycystic Kidney Disease
Related terms Polycystic Kidney, Autosomal Dominant
Enrollment 1,174 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov